AstraZeneca sold its 7.7 percent stake in Moderna for more than $1 billion: Report
New Delhi: AstraZeneca Plc has sold its 7.7% stake in Moderna Inc for more than $1 billion after the U.S. biotechnology company's shares soared on the back of its coronavirus vaccine breakthrough, The Times reported.
The report added that it was not clear over what period British-based AstraZeneca sold its holding in Moderna.
AstraZeneca and Moderna did not immediately respond to requests for comment.
AstraZeneca is retaining partnership with Moderna on other disease treatments and could sell its AstraZeneca/Oxford University Covid-19 vaccine on a commercial basis in future if the virus becomes endemic, the report added.
Moderna, whose vaccine is cleared for emergency use against Covid-19 in the United States, said last week it was expecting sales of $18.4 billion from its coronavirus vaccine this year.
Read also: AstraZeneca, Novavax say tie-up with Serum Institute key to mass production of Covid-19 Vaccines
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd